342 related articles for article (PubMed ID: 33171487)
1. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
[TBL] [Abstract][Full Text] [Related]
2. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
O'Connor OA; Falchi L; Lue JK; Marchi E; Kinahan C; Sawas A; Deng C; Montanari F; Amengual JE; Kim HA; Rada AM; Khan K; Jacob AT; Malanga M; Francescone MM; Nandakumar R; Soderquist CR; Park DC; Bhagat G; Cheng B; Risueño A; Menezes D; Shustov AR; Sokol L; Scotto L
Blood; 2019 Oct; 134(17):1395-1405. PubMed ID: 31471376
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
10. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract][Full Text] [Related]
11. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
12. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
[TBL] [Abstract][Full Text] [Related]
13. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
[TBL] [Abstract][Full Text] [Related]
16. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
[TBL] [Abstract][Full Text] [Related]
17. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
[TBL] [Abstract][Full Text] [Related]
19. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
[TBL] [Abstract][Full Text] [Related]
20. [Romidepsin (Istodax
Ro T; Nakayama N; Achiwa H; Ohtsu T
Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]